Two snakebite antivenoms have potential to reduce Eswatini’s dependency upon a single, increasingly unavailable product: Results of preclinical efficacy testing
Fig 5
SVMP activity of Eswatini venoms and their neutralisation by three antivenoms.
*** indicates p < 0.001, **** indicates p < 0.0001 by one-way ANOVA. A: SVMP activity of B. arietans, D. polylepis, H. haemachatus, N. annulifera and N. mossambica in comparison to PBS control. Data show the mean of four replicates and error bars represent standard deviation. Neutralisation of (B) B. arietans and (C) N. annulifera SVMP activity by the three antivenoms SAIMR Polyvalent (SAVP), Panafrican (ICP) and PANAF (PS&V) at different doses, in comparison to a no antivenom control (venom only) showing 100% activity. Data show the mean of four replicates and error bars represent standard deviation.